Older Americans travel substantially longer distances and times to reach a dermatologist than to reach other outpatient providers, according to a new access-to-care analysis highlighted by Bioengineer.org. The study frames the disparity as a structural barrier for precisely the age group that carries the highest skin-cancer and chronic skin-disease burden.

The findings land at a moment when dermatology workforce distribution is under renewed scrutiny. Specialty care in the United States clusters in metropolitan and academic centers, and older adults — many of whom no longer drive, live on fixed incomes, or manage multiple comorbidities — absorb the travel burden that clustering creates. The analysis maps travel time geographically, rather than counting physicians per capita, which makes the disadvantage visible at the level of the individual patient's trip.

Why does travel time matter more for older patients?

Age is the dominant risk factor for most skin malignancies. Melanoma incidence rises steeply after 50, and non-melanoma skin cancers — basal cell and cutaneous squamous cell carcinoma — occur overwhelmingly in patients 65 and older. The same cohort accumulates chronic inflammatory disease, including late-onset psoriasis and eczema, that requires sustained specialist follow-up rather than a single consult.

A long trip is therefore not an inconvenience but a filter. Patients who cannot arrange transportation, cannot sit through a long drive, or cannot afford repeated trips delay or forgo the periodic total-body skin examinations that catch lesions at thin, curable stages. Delayed presentation is the mechanism by which access gaps convert into worse outcomes, including thicker tumors at diagnosis.

What does the mapping approach show?

By measuring actual travel time rather than straight-line distance or county-level provider counts, the analysis captures real-world friction: road networks, facility locations, and the cumulative cost of repeat visits. Studies of specialty access consistently find that travel-time measures expose disparities that density statistics mask, because a region can look adequately supplied on paper while its dermatologists sit hours away from the patients who need them most.

The pattern the mapping reveals fits the broader geography of American specialty care. Rural counties and regions far from academic medical centers show the longest travel times, while urban older adults typically reach a dermatologist within a routine commute. The result is a two-tier system in which access depends more on ZIP code than on clinical need.

What are the downstream clinical consequences?

For skin cancer, the arithmetic of access is unforgiving. Total-body skin examinations, evaluation of changing pigmented lesions, and surgical follow-up after excision all assume the patient can physically get to the clinic. When a round trip consumes most of a day, patients rationalize skipped appointments, and primary care clinicians — often the only realistic point of contact — must manage what dermatologic evaluation they can offer locally.

For chronic inflammatory disease, the stakes are chronic rather than acute. Psoriasis and eczema in older adults frequently coexist with diabetes, cardiovascular disease, and polypharmacy, so interrupted specialist care raises both dermatologic and systemic risks.

Which fixes follow from the data?

Access analyses of this kind typically point toward a short list of interventions:

• Tele dermatology triage, which can clear routine follow-up from specialist schedules and reserve in-person visits for procedures and full-body exams
• Rotating outreach clinics that bring dermatologists into high-travel-time counties on a scheduled basis
• Teledermatoscopy pathways that let primary care teams submit lesion images for specialist review
• Workforce and reimbursement policies that reward practice location in underserved regions rather than penalizing it

None of these eliminates the need for in-person skin surgery or biopsies, but each reduces the number of trips an older patient must make for the surveillance that precedes them.

The study's contribution is to quantify the barrier in units patients actually experience — minutes and hours behind a wheel or in a waiting shuttle. As the U.S. population over 65 grows, and with it the skin-cancer and inflammatory-disease caseload, travel-time mapping is likely to become a standard tool for deciding where the next teledermatology node or outreach clinic should go, and how quickly.